BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

790 related articles for article (PubMed ID: 32681682)

  • 1. Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study.
    Seto T; Hayashi H; Satouchi M; Goto Y; Niho S; Nogami N; Hida T; Takahashi T; Sakakibara-Konishi J; Morise M; Nagasawa T; Suzuki M; Ohkura M; Fukuhara K; Thurm H; Peltz G; Nishio M
    Cancer Sci; 2020 Oct; 111(10):3726-3738. PubMed ID: 32681682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
    Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
    Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
    Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
    Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Management of Adverse Events Associated with Lorlatinib.
    Bauer TM; Felip E; Solomon BJ; Thurm H; Peltz G; Chioda MD; Shaw AT
    Oncologist; 2019 Aug; 24(8):1103-1110. PubMed ID: 30890623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial.
    Soo RA; Huat Tan E; Hayashi H; Seto T; Lin CC; Ou SI; Kim DW; Liu G; Abbattista A; Martini JF; Hooi Wong C; Toffalorio F; Solomon BJ
    Lung Cancer; 2022 Jul; 169():67-76. PubMed ID: 35660971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
    Shaw AT; Solomon BJ; Chiari R; Riely GJ; Besse B; Soo RA; Kao S; Lin CC; Bauer TM; Clancy JS; Thurm H; Martini JF; Peltz G; Abbattista A; Li S; Ou SI
    Lancet Oncol; 2019 Dec; 20(12):1691-1701. PubMed ID: 31669155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs.
    Felip E; Shaw AT; Bearz A; Camidge DR; Solomon BJ; Bauman JR; Bauer TM; Peters S; Toffalorio F; Abbattista A; Thurm H; Peltz G; Wiltshire R; Besse B
    Ann Oncol; 2021 May; 32(5):620-630. PubMed ID: 33639216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.
    Lee J; Sun JM; Lee SH; Ahn JS; Park K; Choi Y; Ahn MJ
    Clin Lung Cancer; 2019 May; 20(3):215-221. PubMed ID: 30683630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.
    Baldacci S; Besse B; Avrillon V; Mennecier B; Mazieres J; Dubray-Longeras P; Cortot AB; Descourt R; Doubre H; Quantin X; Duruisseaux M; Monnet I; Moro-Sibilot D; Cadranel J; Clément-Duchêne C; Cousin S; Ricordel C; Merle P; Otto J; Schneider S; Langlais A; Morin F; Westeel V; Girard N
    Eur J Cancer; 2022 May; 166():51-59. PubMed ID: 35278825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer.
    Bauer TM; Shaw AT; Johnson ML; Navarro A; Gainor JF; Thurm H; Pithavala YK; Abbattista A; Peltz G; Felip E
    Target Oncol; 2020 Feb; 15(1):55-65. PubMed ID: 32060867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
    Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
    Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
    Cameron LB; Hitchen N; Chandran E; Morris T; Manser R; Solomon BJ; Jordan V
    Cochrane Database Syst Rev; 2022 Jan; 1(1):CD013453. PubMed ID: 34994987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial.
    Shi Y; Fang J; Hao X; Zhang S; Liu Y; Wang L; Chen J; Hu Y; Hang X; Li J; Liu C; Zhang Y; Wang Z; Hu Y; Gu K; Huang J; Zhang L; Shan J; Ouyang W; Zhao Y; Zhuang W; Yu Y; Zhao J; Zhang H; Lu P; Li W; Si M; Ge M; Geng H
    Signal Transduct Target Ther; 2022 Jan; 7(1):25. PubMed ID: 35087031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.
    Solomon BJ; Bauer TM; Mok TSK; Liu G; Mazieres J; de Marinis F; Goto Y; Kim DW; Wu YL; Jassem J; López FL; Soo RA; Shaw AT; Polli A; Messina R; Iadeluca L; Toffalorio F; Felip E
    Lancet Respir Med; 2023 Apr; 11(4):354-366. PubMed ID: 36535300
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Shaw AT; Solomon BJ; Besse B; Bauer TM; Lin CC; Soo RA; Riely GJ; Ou SI; Clancy JS; Li S; Abbattista A; Thurm H; Satouchi M; Camidge DR; Kao S; Chiari R; Gadgeel SM; Felip E; Martini JF
    J Clin Oncol; 2019 Jun; 37(16):1370-1379. PubMed ID: 30892989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab.
    Zhou Y; Jiang W; Zeng L; Mi J; Song L; Lizaso A; Mao X; Yang N; Zhang Y
    Lung Cancer; 2020 May; 143():55-59. PubMed ID: 32208297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
    Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First macrocyclic 3
    Basit S; Ashraf Z; Lee K; Latif M
    Eur J Med Chem; 2017 Jul; 134():348-356. PubMed ID: 28431340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lorlatinib: First Global Approval.
    Syed YY
    Drugs; 2019 Jan; 79(1):93-98. PubMed ID: 30604291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lorlatinib for the treatment of patients with non-small cell lung cancer.
    Akamine T; Toyokawa G; Tagawa T; Yamazaki K; Seto T; Takeo S; Mori M
    Drugs Today (Barc); 2019 Feb; 55(2):107-116. PubMed ID: 30816885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.